David L. Hallal

David L. Hallal
Alma mater B.A. Psychology
University of New Hampshire
Occupation Director and CEO of Alexion Pharmaceuticals[1]
Net worth USD$7,514,610[2]

David L. Hallal is the President and Chief Executive Officer (CEO) of Alexion Pharmaceuticals,[1] the American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).[3][4][5]

Career at Amgen

Main article: Amgen

From 1992 to 2002 Hallal worked at Amgen, the world's largest independent, multinational, biopharmaceutical, biotechnology firm.[6][7] While at Amgen, Hallal focused on Amgen's blockbuster brands Epoetin alfa (brand name Epogen) and Filgrastim (brand name Neupogen), Pegfilgrastim (brand name Neulasta) and Darbepoetin alfa (brand name Aranesp) in the hematology and oncology marketplace, in various escalating leadership positions.[1] During that time he forged "relationships with many of the largest managed care organizations in the U.S."[1] Then as Amgen's Director of Oncology National Accounts in 1998 and 1999 he "played a significant role in developing key long-term partnerships with the nation's largest oncology practice management groups and physician group purchasing organizations."[1]

From 1999 to 2002, he was Sales Director of Southeast Oncology during which time he helped Amgen build its first dedicated hospital sales team. [1]

By 2006 Amgen's Epogen and Aranesp—Epogen's longer-lasting version also known as Darbepoetin alfa (rINN), a synthetic form of erythropoietin— "combined generated an annual worldwide sales of $6.6 billion.[8]

Career Biogen

Main article: Biogen

From August 2002 to February 2004, he was "Senior Director of Sales for Biogen Idec's Immunology Sales Team, where he built a sales organization dedicated to the launch of the first-in-class biologic Alefacept (brand name Amevive) indicated for adults with chronic plaque psoriasis.[1] The manufacturer ceased to produce and market Amevive in 2011 for market reasons.[9]

Career OSI Eyetech

Main article: OSI Pharmaceuticals

From April 2004 to June 2006 he was Vice President of Sales at OSI Eyetech. In 2000 EyeTech Pharmaceuticals, now OSI Pharmaceuticals acquired the license to Pegaptanib, (brand name Macugen), a first-in-class anti-VEGF, anti-angiogenic therapy for the treatment of neovascular (wet) age-related macular degeneration (AMD).[1][10][11] [1] OSI did the late stage development and marketing in the United States for Macugen and Hallal led the U.S. launch of Macugen.[1][11][12]

Career at Alexion Pharmaceuticals, Inc.

In 2006 Hallal became Alexion's Vice President U.S. Commercial Operations reporting to then-President and CEO David Keiser with the mandate to "direct the expected launch of Soliris in the United States.[13] Hallal was responsible "for all U.S. commercial operations including sales, marketing, reimbursement and corporate account management, and customer relations."[13] In 2014 his total annual compensation was USD$696,058.[2]

Starting in November 2008 Hallal was Senior Vice President of Commercial Operations. Starting in May 2010 he was Senior Vice President of Global Commercial Operations at Alexion Pharmaceuticals, Inc. responsible for all Commercial Functions in the U.S. Market, including marketing, sales, and reimbursement/access. From October 2012 to September 2014 he was Chief Commercial Officer and Executive Vice President of Alexion.[1] In September 2014 he became Director of Alexion.[1] In September 2016 he owned approximately 190 thousand Alexion Pharmaceuticals shares worth of almost US$ 25 million.[14]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 "David L. Hallal", Bloomberg, April 2015, retrieved 25 June 2015
  2. 1 2 "Officer Profile Alexion Pharmaceuticals Inc (ALXN.O)", Reuters, 25 June 2015, retrieved 25 June 2015
  3. ↑ "Alexion Submits Application for Soliris". 8 April 2011. Retrieved 25 June 2015.
  4. ↑ "Alexion Pharmaceuticals on the Forbes World's Most Innovative Companies List". forbes.com. Retrieved 28 September 2012.
  5. ↑ Don Seiffert (6 May 2015). "Everything you need to know about the $8.4B acquisition of Synageva". Boston Business Journal. Retrieved 8 May 2015.
  6. ↑ "Jon Entine: New York Times Mum After Congressional Budget Office Rebukes Bungled Amgen/Medicare Investigation". Huffington Post. 26 February 2013.
  7. ↑ "CBO analysis shows keeping oral drugs out of ESRD bundle could save money | Nephrology News & Issues".
  8. ↑ Howard, Samuel (13 March 2008), "FDA Advises Virtual Ban On Amgen, J&J Anemia Drugs", Law360, New York, retrieved 25 June 2015
  9. ↑ "Astellas Pharma US Announces Discontinuation of Manufacturing for Amevive", The Dermatologist, October 2011, retrieved 25 June 2015
  10. ↑ "Macugen (pegaptanib)" (PDF). European Medicines Agency: 1–3. 2010. Retrieved 8 December 2013.
  11. 1 2 "Larry Gold and Craig Tuerk (NeXstar Pharmaceuticals, Boulder, USA)". European Patent Office. 16 February 2011. Retrieved 8 December 2013.
  12. ↑ "2006 Annual Report" (PDF). OSI Pharmaceuticals. 28 February 2007. pp. pg5. Retrieved 20 August 2008. As a result of our decision to divest the eye disease business held by our wholly owned subsidiary, (OSI) Eyetech, Inc., the operating results for (OSI) Eyetech are shown as discontinued operations...
  13. 1 2 "Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations", Alexion, Cheshire, Connecticut, 6 July 2006, retrieved 25 June 2015
  14. ↑ "David Hallal Insider Trading Overview". www.insidermole.com. Retrieved 2016-09-20.


This article is issued from Wikipedia - version of the 9/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.